Beacon Therapeutics gene therapy meets main vision-read goal
Beacon Therapeutics said its experimental gene therapy improved the ability to read in low-light conditions in a late-stage trial for an inherited eye disease that can cause progressive vision loss.
Beacon Therapeutics said on Monday its experimental gene therapy improved the ability to read in low-light conditions in a late-stage trial on people with a form of inherited eye disease that can cause progressive vision loss.Here are some details